Skip to main
PMXSF

Syntara Ltd (PMXSF)


$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy Syntara Ltd (PMXSF) Stock

About Syntara Ltd (PMXSF)

Syntara Ltd. is a clinical stage drug development company, which engages in the development of healthcare products for haematological diseases. Its lead compounds include amsulostat (SNT-5505) and topical pan-LOX inhibitors with SNT-9465. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Frenchs Forest, Australia.
Market cap—
Today's volume—
Revenue (TTM)—
Avg. daily volume—
EBITDA (TTM)-$10.96M
Open—
Price / earnings ratio—
Today's range—
Debt / equity—
52 week range—
5 year debt / equity—
Beta (LTM)—
Interest coverage—
Dividend & yield— (—)
Current ratio—
Ex-dividend date
Next earnings
Dividend payable date

Frequently Asked Questions (FAQ)

How to buy PMXSF stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in PMXSF stock

    Navigate to the Explore page. Then, type PMXSF into the search bar. When you see PMXSF stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased PMXSF stock in your portfolio alongside the rest of your stocks, ETFs, crypto, bonds, options, and your high-yield cash account––all in one place on Public.

Buy Syntara Ltd (PMXSF) Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.